Tools commonly used in the Prostate Screening industry for day-to-day tasks and operations.

• Digital rectal exam (DRE)
• Prostate-specific antigen (PSA) blood test
• Transrectal ultrasound (TRUS)
• Magnetic resonance imaging (MRI)
• Biopsy needle
• Prostate biopsy gun
• Prostate biopsy forceps
• Prostate biopsy needle guide
• Prostate biopsy needle
• Prostate biopsy specimen container

Common products and services typical of NAICS Code 621111-23, illustrating the main business activities and contributions to the market.

• Prostate cancer screening
• Prostate cancer diagnosis
• Prostate biopsy
• Prostate-specific antigen (PSA) testing
• Digital rectal exam (DRE)
• Transrectal ultrasound (TRUS)
• Magnetic resonance imaging (MRI)
• Prostate cancer treatment planning
• Prostate cancer surveillance
• Prostate cancer research

The specific certifications, permits, licenses, and regulatory compliance requirements within the United States for this industry.

• American Registry for Diagnostic Medical Sonography (ARDMS): ARDMS certification is required for sonographers who perform prostate screenings using ultrasound technology. The certification ensures that the sonographer has the necessary knowledge and skills to perform the procedure accurately and safely.
• American Society Of Radiologic Technologists (ASRT): ASRT certification is required for radiologic technologists who perform prostate screenings using X-ray technology. The certification ensures that the technologist has the necessary knowledge and skills to perform the procedure accurately and safely.
• Clinical Laboratory Improvement Amendments (CLIA): CLIA certification is required for laboratories that perform prostate screenings. The certification ensures that the laboratory meets federal standards for accuracy, reliability, and quality control.
• National Certification Board for Therapeutic Massage and Bodywork (NCBTMB): NCBTMB certification is required for massage therapists who perform prostate screenings using massage therapy. The certification ensures that the therapist has the necessary knowledge and skills to perform the procedure accurately and safely.
• Occupational Safety and Health Administration (OSHA): OSHA certification is required for healthcare workers who perform prostate screenings. The certification ensures that the worker has the necessary knowledge and skills to perform the procedure safely and to prevent the spread of infectious diseases.

A concise historical narrative of NAICS Code 621111-23 covering global milestones and recent developments within the United States.

• Prostate screening has been a topic of interest for many years, with the first screening test being developed in the 1980s. The prostate-specific antigen (PSA) test was introduced in the late 1980s and became widely used in the 1990s. In 2012, the US Preventive Services Task Force recommended against routine PSA screening for prostate cancer, citing concerns about overdiagnosis and overtreatment. However, in recent years, there has been a renewed interest in prostate screening, with new tests and technologies being developed to improve accuracy and reduce the risk of unnecessary treatment. For example, the Prostate Health Index (PHI) test, which combines PSA with other biomarkers, has been shown to be more accurate than PSA alone. Additionally, MRI-guided biopsy has been shown to be more accurate than traditional biopsy methods, reducing the need for repeat biopsies and improving patient outcomes.

The anticipated future trajectory of the NAICS 621111-23 industry in the USA, offering insights into potential trends, innovations, and challenges expected to shape its landscape.

• Growth Prediction: Stable

  The future outlook for the Prostate Screening industry in the USA is positive. The industry is expected to grow due to the increasing awareness of prostate cancer and the importance of early detection. The aging population in the US is also expected to contribute to the growth of the industry. Technological advancements in screening methods and treatments are also expected to drive growth in the industry. However, the industry may face challenges due to the COVID-19 pandemic, which has led to a decrease in the number of screenings. Despite this, the industry is expected to recover and continue to grow in the coming years.

Recent groundbreaking advancements and milestones in the Prostate Screening industry, reflecting notable innovations that have reshaped its landscape.

• MRI-Guided Biopsy: This innovation allows for more accurate detection of prostate cancer and reduces the need for multiple biopsies.
• Liquid Biopsy: This non-invasive test detects cancer cells in the blood and can be used to monitor the progression of prostate cancer.
• 3D Prostate Mapping: This technology creates a detailed map of the prostate, allowing for more accurate detection and treatment of prostate cancer.
• Focal Therapy: This treatment targets only the cancerous area of the prostate, reducing the risk of side effects associated with traditional treatments.
• Precision Medicine: This approach uses genetic testing to determine the best treatment for each individual patient, improving treatment outcomes and reducing side effects.
• Telemedicine: This technology allows patients to receive consultations and follow-up care remotely, improving access to care and reducing the need for in-person visits.
• Artificial Intelligence: AI can be used to analyze medical images and detect abnormalities, improving the accuracy of prostate cancer screening.
• Targeted Ultrasound: This technology uses sound waves to target and destroy cancer cells in the prostate, reducing the need for surgery or radiation therapy.
• Biomarker Testing: This test measures certain proteins in the blood that can indicate the presence of prostate cancer, improving the accuracy of screening.
• Active Surveillance: This approach involves monitoring the progression of prostate cancer without immediately treating it, reducing the risk of side effects associated with treatment.